Emerging, challenging, and critical: Thyroid eye disease is one of the newest frontiers in Ora’s portfolio. The challenge: TED’s wide-ranging symptoms and variable progression make consistent endpoints and reliable measurements tough to achieve. Our approach: Ora combines deep ophthalmic trial expertise with rigorous imaging, clinical assessments, and standardised protocols to bring clarity to this complex indication. By partnering closely with investigators and sponsors, we help accelerate therapies that improve outcomes for patients living with TED. From our roots in ocular allergy to emerging indications like TED, Ora continues to lead with innovation and patient focus. #IndicationSpotlight #ThyroidEyeDisease #OphthalmologyResearch #ClinicalTrials #TeamOra
Ora tackles thyroid eye disease with innovative clinical trials.
More Relevant Posts
-
ENMs in Rodent Models of Allergic Lung Disease 🌬️ When nanomaterials meet a sensitised lung. This chapter examines allergic airway responses to nanomaterials in rodent models—offering clues for human respiratory health risks. James C Bonner
To view or add a comment, sign in
-
Current AATD management strategies include lifestyle modifications. For example, smoking accelerates lung disease so patients should be directed to stop smoking. Obesity and alcohol promote liver fibrosis, so maintaining a healthy body weight and avoiding alcohol is recommended. 🫁 As previously mentioned, augmentation therapy is indicated for specific patients with AATD-related lung disease. Several vaccinations can be considered in terms of preventing lung infection and liver disease (hepatitis A and hepatitis B viruses).14 In this module, a gastroenterology/hepatology expert discusses the pathophysiology of alpha-1 antitrypsin deficiency (AATD), importance of early diagnosis, multidisciplinary management strategies, and data on emerging therapies for treating AATD and its related liver and lung diseases. Review the full module here and earn CE/CME: https://bit.ly/4mOEaxC #CE #CME #MedicalEducation
To view or add a comment, sign in
-
-
Clesrovimab for Prevention of RSV Disease in Healthy Infants - The recently FDA-approved antibody against RSV prevented RSV-associated hospitalization of infants within 150 days with an efficacy of 84.2%. The antibody also prevented RSV-associated medically attended lower respiratory infections with an efficacy of 60.4% when compared to placebo controls. The Phase 2b-3 trial monitored 3614 infants. 2412 infants were treated with an injection of clesrovimab (intramuscular, 105-mg dose), whereas 1202 received placebo. Clesrovimab (Enflonsia, Merck) acts by binding to the prefusion F protein of RSV and neutralizing virus entry into host cells. The findings suggest that a single-dose of the antibody in healthy preterm and full-term infant can be used to reduce the incidence of RSV-associated lower respiratory infections and hospitalizations. https://sco.lt/8KqIbo #RSV #clesrovimab #Enflonsia #FDA #CDC #WHO #NIH #NIAID #ECDC #health #globalhealth #publichealth #medicine #Enantapharmaceuticals #clinicaltrials
To view or add a comment, sign in
-
-
Home-Based Ig Therapy: Fewer Infections, Less Antibiotics 💉🏠 Adults with primary immunodeficiency diseases (PIDDs) who self-administer immunoglobulin replacement therapy (IgRT) at home experience: ✅ Lower infection rates (83% vs 90%) ✅ Reduced antibiotic use (81% vs 87%) The convenience of self-administered Ig therapy at home empowers patients while improving outcomes. A real win for independence and health! Learn more: 🔗 https://lnkd.in/erKSpuQs #PrimaryImmunodeficiency #IgTherapy #HomeCare #PatientOutcomes #Immunology #SpecialtyPharmacy
To view or add a comment, sign in
-
-
💨 Everyday nasal spray shows surprising power against COVID—and more A simple over-the-counter nasal spray, already used worldwide for allergies, may also protect against COVID-19. In a phase 2 clinical trial led by Saarland University, Germany, researchers tested azelastine, a medication available in more than 70 countries. Over eight weeks, only 2.2% of people using the spray contracted COVID-19—compared to 6.7% in the placebo group. That’s a two-thirds reduction in cases. Even more intriguing, azelastine also appeared to reduce symptomatic infections, respiratory illnesses, and even rhinoviruses (the common cold), hinting at broader antiviral effects. Scientists think the spray works by blocking viral replication directly in the nose and upper airways—the entry point for most respiratory pathogens. Because it’s already approved for hay fever and allergies, azelastine could become an accessible, low-cost preventive option. While it’s not yet authorized as a COVID treatment, researchers say it may be especially useful for vulnerable individuals and during seasonal surges of respiratory infections. Larger, multicenter studies are now needed to confirm these results. 📖 Source: Lehr T, Meiser P, Selzer D, et al. Azelastine Nasal Spray for Prevention of SARS-CoV-2 Infections: A Phase 2 Randomized Clinical Trial. JAMA Internal Medicine, September 2, 2025. credit: Science Explorist #COVID19 #NasalSpray #Azelastine #RespiratoryHealth #Virology #PublicHealth #ClinicalTrials #InfectionPrevention #ScienceNews #MedicalResearch
To view or add a comment, sign in
-
-
In an undiagnosed patient, could active infection with Echinococcus spp.—whether presenting as disseminated alveolar echinococcosis (E. multilocularis) or hydatid disease (E. granulosus)—manifest clinically with symptoms mimicking allergic disorders, including severe hypersensitivity reactions, and be associated with elevated serum IgE levels as part of the host immune response to parasitic antigens? The following document titled "Underecognized Allergic Manifestations of Active Echinococcosis: A Comprehensive Clinical and Immunological Analysis" is for your interest. #Echinococcosis #CysticEchinococcosis #AlveolarEchinococcosis #HydatidDisease #ParasiticDiseases #NeglectedTropicalDiseases #ZoonoticDiseases #OneHealth #Parasitology #Immunology #InfectiousDiseases #AllergicDiseases #Type2Immunity #IgE #Eosinophilia #Anaphylaxis #Urticaria #Angioedema #Hypersensitivity #AsthmaMimicry #ImmuneModulation #MedicalResearch
To view or add a comment, sign in
-
Dr. Ronald Klatz, MD, DO Worldhealth.net Researchers finally identified where gluten reactions begin: #gut lining cells actively present gluten fragments to immune cells, triggering celiac disease. This breakthrough opens doors to targeted therapies beyond strict gluten avoidance. Millions may benefit. #worldhealth #celiacdisease #glutenfree #autoimmunity #guthealth #immunology #medicalresearch #regenerativemedicine #medicine #health #wellness #antiaging https://lnkd.in/gpjb5-TY
To view or add a comment, sign in
-
-
While histamine intolerance is on the milder to moderate side of the spectrum, Mastocytosis is the most severe form of mast cell issues. Unlike mast cell activation syndrome (MCAS), mast cell mastocytosis is often overlooked, taking patients nearly a decade to get diagnosed. Symptoms often span multiple organs and can include skin rashes, gastrointestinal distress, and life-threatening anaphylaxis. To dive into this topic, I’m joined by Dr. Mariana Castells, M.D., Ph.D., a physician and researcher at Brigham and Women's Hospital with over 30 years of experience in allergy and immunology. EPISODE HIGHLIGHTS: - What is mastocytosis (and why it’s so often missed) - Shocking link between bone loss + mast cell MCAS disorders - Early warning signs to look for - Why high-histamine foods aren't your biggest histamine problem - Newest mastocytosis treatment options - If you suspect MCAS mast cell or Mastocytosis, here are your next steps! FULL EPISODE: https://lnkd.in/eYQqwjxs
To view or add a comment, sign in
-
Open Access: Associations Between Blood Eosinophil Surface Proteins and Clinical Traits in Severe Asthma and Chronic Rhinosinusitis With Nasal Polyposis. Corresponding author: Emeline Delaunay Read the article here: doi.org/10.1111/all.70001 Delaunay et al. identified elevated CD125 expression in circulating eosinophils of patients with severe asthma and chronic #rhinosinusitis with nasal polyps (#CRSwNP). Surface markers on blood eosinophils were correlated with phenotypical and treatable clinical traits in severe asthma and CRSwNP, providing potential new biomarkers of disease. Read more articles published in #Allergy on #asthma here: https://lnkd.in/dvHaYziZ #allergy_journal
To view or add a comment, sign in
-
-
Molecule Spotlight: IgE: The Parasite Antibody Immunoglobulin E (IgE) is a powerful antibody in humans, best known for its role in allergies, but its evolutionary “day job” is fighting parasites. When helminths (worms like Schistosoma or Ascaris) invade, IgE binds to parasite antigens and arms immune cells such as eosinophils, basophils, and mast cells. These cells then release toxic granules and inflammatory mediators that help damage or expel the parasite. In regions where parasitic infections are common, IgE levels are often very high, a reflection of the body’s ongoing battle with these invaders. Interestingly, the same IgE responses that protect us from parasites can also “misfire,” leading to allergic diseases like asthma or hay fever in parasite-free environments. This dual role makes IgE a fascinating example of how evolution shapes our immune system, balancing defense and disease. #ParasiteWatch #MoleculeSpotlight #Parasitology #Immunology #GlobalHealth #InfectiousDiseases #Helminths #SciComm
To view or add a comment, sign in
-
Explore content categories
- Career
- Productivity
- Finance
- Soft Skills & Emotional Intelligence
- Project Management
- Education
- Technology
- Leadership
- Ecommerce
- User Experience
- Recruitment & HR
- Customer Experience
- Real Estate
- Marketing
- Sales
- Retail & Merchandising
- Science
- Supply Chain Management
- Future Of Work
- Consulting
- Writing
- Economics
- Artificial Intelligence
- Employee Experience
- Workplace Trends
- Fundraising
- Networking
- Corporate Social Responsibility
- Negotiation
- Communication
- Engineering
- Hospitality & Tourism
- Business Strategy
- Change Management
- Organizational Culture
- Design
- Innovation
- Event Planning
- Training & Development